Mannitol for Posterior Fossa Hemorrhage Systematic Review Ncbi
J Stroke. 2017 January; 19(1): 28–39.
Spontaneous Intracerebral Hemorrhage: Management
Received 2016 Dec 6; Revised 2017 Jan 17; Accepted 2017 Jan 17.
Abstruse
Spontaneous non-traumatic intracerebral hemorrhage (ICH) remains a meaning crusade of mortality and morbidity throughout the world. To improve the devastating class of ICH, various clinical trials for medical and surgical interventions have been conducted in the terminal 10 years. Recent large-calibration clinical trials take reported that early intensive claret pressure reduction can be a safe and feasible strategy for ICH, and accept suggested a prophylactic target range for systolic blood pressure. While new medical therapies associated with warfarin and non-vitamin K antagonist oral anticoagulants have been developed to treat ICH, contempo trials take non been able to demonstrate the overall beneficial effects of surgical intervention on mortality and functional outcomes. Nonetheless, some patients with ICH may benefit from surgical direction in specific clinical contexts and/or at specific times. Furthermore, clinical trials for minimally invasive surgical evacuation methods are ongoing and may provide positive prove. Upon agreement the current guidelines for the management of ICH, clinicians can administrate appropriate treatment and attempt to improve the clinical outcome of ICH. The purpose of this review is to assistance in the conclusion-making of the medical and surgical direction of ICH.
Keywords: Stroke, Cerebrovascular disorders, Intracranial hemorrhages, Cerebral hemorrhage, Therapeutics
Introduction
Spontaneous non-traumatic intracerebral hemorrhage (ICH) is the second near prevalent subtype of stroke and is associated with high mortality and morbidity throughout the world [1 - iii]. Various clinical trials related to the medical and surgical management of ICH take been conducted to overcome its devastating clinical course. Despite these efforts in the past decades, there have been no dramatic advances in the development of interventions to meliorate the functional outcomes after ICH [four]. In this situation, many clinicians may misunderstand that effective treatment options are lacking; notwithstanding, the necessity of excellence in clinical care and enquiry should be emphasized rather than underestimated. In this review, we talk over previous clinical trials and the current guidelines for the direction of spontaneous ICH; ongoing clinical trials are too included. For this purpose, a systematic literature review was conducted with total PubMed searches for all the English language manufactures about the management of ICH, regardless of the date of publication.
Initial evaluation and management
In terms of the pathogenesis of ICH resulting from bursting of intracerebral arteries, a bulk of fatalities occur in the first two days of the onset of symptoms [5 , 6]. Furthermore, nearly one-fifth of the patients with ICH experience neurological deterioration in the pre-hospitalization period [7], and one-fourth of the patients in the hospitalization flow [8]. Rapid initial diagnosis and concentrated management are crucial in the early management of ICH. When a patient presents with focal neurological deficits, severe headache, airsickness, high systolic blood pressure (SBP) greater than 220 mmHg, and decreased consciousness with a sudden onset, ICH should be the first condition considered in the diagnosis. In addition to clinical presentation, a brief medical history including hypertension, prior stroke, recent caput trauma, and prior use of antithrombotic drugs including anticoagulants, should besides be recorded. After a quick assessment of the medical history and presentation, neuroimaging should be performed to ostend the diagnosis. Brain computed tomography (CT) is the gold standard for identifying acute hemorrhage; magnetic resonance imaging (MRI) can be an alternative with an reward of being able to differentiate between the acute and chronic stages of hemorrhage [9 , 10].
In add-on to the initial diagnosis of ICH at the emergency room, acute direction should be cooperated at the aforementioned fourth dimension. The main principle for the early management of ICH is the aforementioned as that for the direction of ischemic stroke [11]. Airway management (if needed), cardiovascular support, urgent BP lowering treatment, and reversal of coagulation abnormalities should exist initiated at the emergency room. Critical protocols developed for the direction of ICH may permit more than efficient, standardized, and integrated management of patients with ICH and reduce the length of stay at the emergency room past facilitating their prompt admission to a stroke unit or a neuroscience intensive intendance unit [12].
Various grading scales are used for predicting the prognosis in the early stages of ICH [v , 13 - 17]. The ICH score is the more often than not commonly used scale and can be easily calculated based on neurological examination and CT findings (Table ane) [5]. In prospective observational cohort studies, the ICH score could exist a valid clinical grading calibration for the xxx-day mortality (Figure one) [five] and 12-calendar month functional outcome [15].
The ICH Score and 30-twenty-four hour period mortality. Data were revised from Hemphill JC 3rd, Bonovich DC, Besmertis L, Manley GT, Johnston SC. The ICH score: a unproblematic, reliable grading scale for intracerebral hemorrhage. Stroke 2001;32:891-897. There was no patient with a score of 6 in the cohort, merely an ICH score of half dozen would exist predicted to be associated with a high risk of mortality.
Table ane.
Decision of the ICH score
| Component | ICH Score Points |
|---|---|
| GCS score | |
| 3–four | 2 |
| five–12 | i |
| 13–15 | 0 |
| ICH volume (cm3) | |
| ≥ 30 | 1 |
| < 30 | 0 |
| IVH | |
| Aye | 1 |
| No | 0 |
| Infratentorial origin of ICH | |
| Yep | one |
| No | 0 |
| Age (yr) | |
| ≥ 80 | 1 |
| < 80 | 0 |
| Total ICH Score | 0–6 |
Medical direction
Recommendations for medical management of ICH are summarized in Tabular array 2 and described below.
Table 2.
Medical management of ICH
| Component | Recommendation |
|---|---|
| Blood pressure | For patients with SBP > 150 mmHg and ≤ 220 mmHg, early intensive BP-lowering treatment with a target of 140 mmHg can exist a safe and effective method. |
| For patients with SBP > 220 mmHg, aggressive BP reduction with a continuous intravenous infusion of BP lowering drugs, such as nicardipine, should be considered. | |
| Anticoagulation-related ICH | Withhold anticoagulants and right INR, if elevated, by intravenous infusion of vitamin Thousand and FFP. |
| PCCs can be considered rather than FFP given its fewer complications and ability to speedily correct the INR. | |
| Antiplatelet medication-related ICH | Consider platelet transfusions, although the testify is unclear. |
| Thromboprophylaxis | Utilize intermittent pneumatic compression at admission to prevent venous thromboembolism. |
| Low-molecular-weight heparin or unfractionated heparin tin be practical afterwards cessation of haemorrhage in immobile patients. | |
| Systemic anticoagulation or IVC filter can be considered in patients with symptomatic DVT or pulmonary thromboembolism. | |
| ICP | Patients with decreased level of consciousness can be treated by ventricular drainage of the hydrocephalus, if needed. |
| Hypertonic saline or mannitol tin exist used accordingly. | |
| Fever | Fever should be treated with antipyretic medication and/or external or internal cooling methods to foreclose poor outcomes. |
| Glucose | Regular monitoring and control of glucose is essential to prevent both hyperglycemia and hypoglycemia. |
| Seizure | Clinical seizures are frequent among patients with ICH and should be treated. |
| Electrographic seizures with decreased level of consciousness should be treated. | |
| Continuous EEG monitoring can exist beneficial in patients with depressed mental condition that is not explainable past hemorrhage. |
Monitoring and nursing intendance
The condition of patients with ICH frequently deteriorates within the first 24 or 48 hours after symptom onset because of secondary injuries acquired past hematoma expansion, intraventricular hemorrhage (IVH) extension, fever, and high blood pressure [18 - 20]. Hence, patients in the astute phase of ICH should be monitored and taken care of in facilities in which the close monitoring of the patient's status and frequent administration of medications are possible. In a prospective observational written report, the patients admitted to a specialized neuroscience intensive care unit of measurement (ICU) showed reduced mortality compared to those admitted to the full general ICU [21]. In a Swedish cohort written report with 86 hospitals and 105,043 patients, care in the stroke unit was associated with better long-term survival in patients with ICH [22]. Specialized care units such equally the neuroscience ICU and stroke unit can provide close monitoring of blood pressure level (BP), heart rate, electrocardiograph findings, oxygen saturation, and neurological status in medically and neurologically unstable patients in the early stage of ICH. The intracranial force per unit area (ICP), cognitive perfusion pressure level, and continuous intra-arterial blood pressure level (BP) can also be monitored.
Claret pressure level reduction
Based on the viewpoint that increased BP causes greater fierce of blood vessels and flow-out of claret through these vessels and somewhen leads to the expansion of the hematoma, high BP is considered to be associated with hematoma expansion and poor outcomes, especially early neurological deterioration, bloodshed, and dependency [23 - 25]. Thus, intensive BP reduction is thought to reduce hematoma expansion and improve the clinical outcomes in patients with ICH. However, the therapeutic goals of BP reduction in the early on phase of ICH are non clearly defined. The cardinal betoken to contend is whether astute BP reduction results in ischemic insult to perihematomal penumbral lesions surrounding the hemorrhage [26]. On the other hand, a randomized clinical trial showed that rapid BP reduction targeting an SBP of <150 mmHg did not reduce perihematomal cerebral blood catamenia on CT perfusion imaging farther than that targeting an SBP of <180 mmHg [27].
Recently, a few randomized clinical trials were performed to place therapeutic targets and evaluate the safety of intensive BP reduction in the early phases of ICH [28 - 30]. The airplane pilot phase of the Intensive Claret Pressure Reduction in Astute Cerebral Hemorrhage (Collaborate 1) trial enrolled 404 patients with astute spontaneous ICH inside half-dozen hours of symptom onset from Australia, China, and South korea [29]. They compared the early on intensive BP lowering group (target SBP, 140 mmHg) to the standard guideline-based grouping (target SBP, 180 mmHg). The primary outcome was proportional change in the hematoma volume at 24 hours. In 2008, the results showed that the mean hematoma expansion at 24 hours was greater (P=0.04) in the guideline-based group (36.3%) than in the intensive BP lowering group (13.7%) [29 , 31]. After controlling for the effects of the initial hematoma volume and the onset-to-CT time, the median hematoma expansion was 16.2% in the guideline-based group and 6.2% in the intensive BP lowering group (P=0.06) [29]. At that place were no differences in the 90-day functional outcomes and adverse events between the 2 treatment groups [29].
In 2010, the Antihypertensive Treatment of Acute Cerebral Hemorrhage (ATACH) trial reported similar results about the safety of early intensive BP lowering handling. This study was an open-label pilot study designed to evaluate the feasibility and safety of three escalating levels of antihypertensive handling with the intravenous administration of nicardipine in patients with ICH-related astute hypertension [30]. Patients with ICH and an SBP ≥170 mmHg who presented within half-dozen hours of the onset of symptoms were enrolled. Continuous intravenous nicardipine was administered to accomplish a target SBP of 170–200 mmHg in the starting time grouping (n=18), 140–170 mmHg in the second group (due north=20), and 110–140 mmHg in the third group (n=22). The investigators found no pregnant relationship between BP reduction and any of the upshot measurements (hematoma expansion, higher perihematomal edema ratio, and poor iii-month modified Rankin scale score).
Recently, the results of the largest randomized clinical trial evaluating the efficacy of intensive BP lowering were published [28]. The INTERACT ii trial is a phase 3 trial enrolling ii,839 patients with an SBP betwixt 150 and 220 mmHg within 6 hours of the ICH. The participants were randomized to the intensive treatment group (target SBP, <140 mmHg) or the standard treatment grouping (target SBP, <180 mmHg). The BP lowering therapy was started within ane hour of randomization and connected for a duration of seven days. The investigators constitute that the intensive handling group was less probable to accept the chief issue of decease or major disability (modified Rankin scale score ≥3; OR [odds ratio], 0.87; 95% CI [confidence interval], 0.75–i.01; P=0.06) [iv , 28]. Ordinal analysis showed that the intensive handling decreased the odds of higher modified Rankin scale scores (OR, 0.87; 95% CI, 0.77–1.00; P=0.04) [28]. The incidence of nonfatal serious adverse events did not differ between the two treatment groups.
In 2016, the results of the ATACH 2 trial [32] were reported. The purpose of this trial was to determine the efficacy of rapidly lowering SBP in patients with ICH in an before fourth dimension window than that evaluated in previous trials. A total of 1,000 patients with ICH were randomized to intensive BP lowering (target SBP, 110-139 mmHg) or standard BP lowering (target SBP, 140-179 mmHg). Intravenous nicardipine inside 4.5 hours of the onset of symptoms was used equally a method of BP reduction, which was earlier compared to the 6-hour time-point in the INTERACT two trial. The main effect of death or disability (modified Rankin scale score of four to 6) at 3 months after randomization was achieved in 38.7% of the patients in the intensive treatment grouping and in 37.vii% of the patients in the standard treatment group (adjusted relative chance [RR], one.04; 95% CI, 0.85-1.27; P=0.72) [32]. While the incidence of hematoma expansion, divers as a >33% increase in the ICH book over the initial 24 hours afterward the onset of symptoms, was lower in the intensive treatment (18.9%) group than in the standard treatment group (24.iv%), the divergence between the groups was not statistically significant (P=0.08). There was no significant difference in the incidence of treatment-related serious adverse events within 72 hours of the onset of symptoms.
Overall, the current evidence supports that early on intensive BP lowering is condom and viable, and is associated with a modestly better functional outcome. The 2015 American Heart Association/American Stroke Association guidelines for the management of spontaneous ICH recommend early BP reduction with an SBP target of 140 mmHg for patients with ICH presenting with an SBP between 150 and 220 mmHg and without whatsoever contraindication to acute BP treatment [iv]. For patients with ICH presenting with an SBP >220 mmHg, aggressive BP reduction with continuous intravenous infusion and frequent BP monitoring may be reasonable.
Anticoagulation-related intracerebral hemorrhage
The clinical outcomes of vitamin Thousand antagonists (VKA)-related ICH are poor. Therefore, in addition to stopping VKA, urgent measures are usually needed to opposite the effects of VKA in patients with an elevated international normalized ratio (INR) [ii]. Intravenous vitamin G administration at a dose of 5-10 mg should be initiated in the offset hours of symptom presentation. Fresh-frozen plasma, along with vitamin Yard, has been used for the rapid correction of INR for years. Recently, prothrombin complex concentrates (PCCs), activated PCC factor Eight inhibitor bypassing activity (FEIBA), and recombinant activated factor VIIa (rFVIIa) have been evaluated as potentially more constructive alternatives [4].
Reversal of non-vitamin Yard adversary oral anticoagulants (NOACs)-related ICH has been poorly evaluated. Recently, idarucizumab, a monoclonal antibody designed for the reversal of anticoagulant furnishings of dabigatran, has been introduced into medical practice as the commencement antidote for NOACs [33 , 34]. Furthermore, hemodialysis tin can exist used in case of dabigatran [35]. Andexanet alfa, a specific reversal amanuensis to neutralize the anticoagulant effects of factor Xa inhibitors such as rivaroxaban, apixaban, and edoxaban, is presently in phase 3 clinical trials [35 - 37]. Potential reversal strategies using FEIBA, other PCCs, rFVIIa, or activated charcoal might be considered [four , 35].
In contrast to VKA, NOACs do not require hematological monitoring because they have dissimilar furnishings and sensitivities on screening coagulation tests including the prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin clotting time (TT) [38 , 39]. Rest furnishings of NOACs can be estimated based on the elimination half-life of each NOAC and the renal role of individuals on NOACs [39]. When the NOAC condition of the patient is unknown, a coagulation assay tin be performed to estimate the presence and concentration of NOACs in the body. Dabigatran is a straight thrombin inhibitor, and a high aPTT at trough may be associated with a higher hazard of haemorrhage, and a normal aPTT in dabigatran-treated patients has been used in emergency situations to exclude any residual anticoagulant effect [39 - 42]. Rivaroxaban, a straight gene Xa inhibitor, tin can prolong the PT significantly [43]. Apixaban, some other straight gene Xa inhibitor, may be associated with prolonged PT and aPTT, merely normal PT and aPTT practice not rule out significant anticoagulant furnishings [39]. Thus, a drug-specific anti-factor Xa chromogenic assay is necessary [44].
As the optimal timing for resumption of anticoagulation later on anticoagulation-related ICH is unknown, the risk of both cardioembolic events and recurrent anticoagulation-related ICH should be considered together in determining the starting time of anticoagulation [45 , 46]. In full general, resumption of VKA within the first month is associated with a high risk of recurrent ICH [47]. Therefore, a delay of at least 1 month should be suggested in patients with VKA-related ICH [4]. However, early resumption of anticoagulation may exist needed in patients with prosthetic center valves because of the high gamble of cardioembolic events [4]. In patients with lobar ICH, resumption of anticoagulation is reported to be associated with higher risk of recurrent ICH compared with deep hemispheric hemorrhage (1-yr run a risk of recurrence, 15% versus 2.1%) [48 , 49]. Therefore, abstention of long-term anticoagulation with VKA equally a treatment for nonvalvular atrial fibrillation is probably recommended in patients with VKA-associated lobar ICH [4]. The prophylactic of antiplatelet agents every bit alternatives to VKA in patients with lobar ICH is controversial [50 , 51]. In patients with non-lobar ICH, antiplatelet monotherapy tin can exist a safer alternative to VKA in some patients with atrial fibrillation [4 , 51 , 52]. As alternatives to VKA after ICH, the usefulness of NOACs including dabigatran, rivaroxaban, and apixaban, remains unknown [4 , 53 - 55].
Antiplatelet medication-related intracerebral hemorrhage
The effect of antiplatelet drugs on the effect of ICH is uncertain. Two observational studies showed that reduced platelet activity is associated with IVH, death, early ICH growth, and poor functional outcome [56 , 57]. Another report reported that the use of antiplatelet medication at the onset of ICH symptoms was non associated with increased hemorrhage volume, hematoma expansion, or poor functional outcome [58]. Platelet transfusion might be considered in patients with acute ICH with prior antiplatelet use or platelet dysfunction, although at that place has been no randomized controlled trial testing this. Two trials on platelet transfusion in patients with ICH are ongoing [two , 59].
Thromboprophylaxis in intracerebral hemorrhage
Thromboprophylaxis in patients with acute ICH is a complicated trouble. The risk of haemorrhage is not low, and the run a risk of venous thromboembolism is high. Therefore, thromboprophylaxis should not exist delayed [4]. The incidence of symptomatic venous thromboembolism ranges from 0.5% to 13%, while that of pulmonary embolism ranges from 0.vii% to 5% [sixty]. Methods for thromboprophylaxis were suggested through three different trials termed the CLOTS trials (Clots in Legs or Stockings After Stroke) I-Three [61 - 64]. The results suggested that intermittent pneumatic compression started every bit early on equally the day of hospitalization could reduce the occurrence of proximal deep vein thrombosis (DVT), and that graduated compression stockings were not constructive.
Systemic anticoagulation or inferior vena cava (IVC) filter placement are probably indicated in patients with ICH with symptomatic DVT or pulmonary embolism [4]. One meta-assay found that early anticoagulation, including low-molecular-weight heparin or unfractionated heparin or heparinoids, is associated with a significant reduction in pulmonary embolism and a non-significant increment in hematoma enlargement [65]. An IVC filter is normally not recommended in patients with acute DVT of the leg in add-on to anticoagulant therapy. However, if anticoagulation therapy is contraindicated, an IVC filter can be used [66].
ICP and cerebral edema direction
Intracranial hypertension following ICH is common, especially in younger patients with supratentorial hemorrhage [67]. The most common causes of intracranial hypertension are hydrocephalus from IVH and surrounding edema from hematoma. Hence, ICP monitoring and direction should exist considered in patients with large hematomas or those at high risk for hydrocephalus, such as patients with a Glasgow blackout scale (GCS) score of ≤eight, clinical evidence of transtentorial herniation, or pregnant IVH or hydrocephalus [iv]. ICP tin be measured past catheterization into the cerebral ventricles or encephalon parenchyma. The decision to use these catheters should be based on whether there is a need to drain the cerebrospinal fluid to treat the hydrocephalus or elevated ICP [4]. In instance of patients with hydrocephalus and decreased consciousness, ventricular catheterization and drainage is a reasonable method for ICP monitoring and management.
Methods for the medical direction of ICP consist of caput elevation to 30°, hyperventilation, mild sedation, and hyperosmolar therapy with hypertonic saline or mannitol. Mannitol tin exist administered intravenously, just special attention should exist paid to volume depletion. Although hypertonic saline may require a primal venous catheter, it tin can be more than effective [68]. Corticosteroids should be avoided because of their significant harmful furnishings such as infections without demonstrable beneficial effects [69].
Fever and temperature control
The incidence of fever after supratentorial ICH is loftier, particularly in patients with ventricular hemorrhage. Fever has been reported to worsen the outcomes in patients with ICH. In patients who survive the outset 72 hours after hospitalization, the elapsing of fever is associated with poor functional outcome and seems to be an independent prognostic factor [70]. Therefore, temperature should be regularly measured in patients with ICH. Antipyretics are typically a unproblematic method to reduce mild fever. External cooling devices and intravascular cold saline infusion can be used in unlike clinical settings. Preliminary studies accept suggested that therapeutic cooling may reduce perihematomal edema [71 , 72]. Handling with mild hypothermia in ICH should be considered investigational at this time. Although the benign result of fever treatment has non been demonstrated in patients with ICH, maintenance of normothermia is reasonable and recommended in guild to reduce secondary brain injury.
Glucose management
Hyperglycemia on admission is associated with an increased 28-solar day case fatality in both nondiabetic and diabetic patients with ICH [73]. Therefore, hyperglycemia should be controlled fairly. On the other hand, tight glucose control with intensive insulin therapy is as well reported to be associated with reduced cognitive extracellular glucose availability and increased mortality [74 , 75]. Therefore, glucose level should be monitored regularly and both hyperglycemia and hypoglycemia should exist avoided [four].
Seizure management
Studies using continuous electroencephalography (EEG) showed that electrographic seizures occurred in up to one third of the patients with ICH [76 - 78]. Clinical seizures are as frequent equally 16% inside 1 week after ICH and the location of the hematoma influences this frequency; cortical involvement is a crucial take chances cistron of early on seizures [76 , 79 , 80]. Although the association betwixt electrographic seizures and clinical outcomes is unclear, there is a consensus that both clinical seizures and electrographic seizures with decreased consciousness should exist treated. In the example that patients with ICH presenting with decreased mental status of unknown etiology, continuous EEG monitoring is essential to detect electrographic seizures. With respect to the safe use of antiepileptic drugs for ICH, in that location is no evidence supporting their benign effects. Therefore, the prophylactic use of antiepileptic drugs is not recommended [iv].
Medical complications
The frequency of medical complications after ICH was reported in a randomized clinical trial of the prophylactic of neuroprotectant employ in patients with ICH. The most mutual medical complications were pneumonia (five.7%), pulmonary embolism (two.3%), respiratory failure (2.0%), aspiration pneumonia (ii.0%), sepsis (one.three%), and urinary tract infection (0.7%) [81]. Among medical complications, pulmonary complications including pneumonia, neurogenic pulmonary edema, and pulmonary embolism were seen to be the most frequent complications. 1 retrospective cohort report reported that i-third of the patients with ICH developed pulmonary complications [82]. Since dysphagia and aspiration are crucial risk factors for pneumonia, formal screening for dysphagia may reduce the risk of development of pneumonia in patients with ischemic stroke [83]. Other medical complications in patients with ICH include cardiac events and death caused by acute myocardial infarction, heart failure, ventricular arrhythmias, cardiac arrest, acute kidney failure, hyponatremia, gastrointestinal bleeding, and mail-stroke depression [four]. As medical complications are associated with high chance of mortality in patients with ICH usually after 7 days of hospitalization [4], comprehensive screening, monitoring, and appropriate care for each medical complication should back-trail the standard management regime for ICH.
Palliative intendance and withdrawal of technological support
The importance of palliative intendance and withdrawal of technological support has recently been highlighted. The American Center Association/American Stroke Association have published a scientific argument addressing these problems in patients with stroke [84]. The withdrawal of technological support including Do-Not-Resuscitate (DNR) orders must be considered at an individual level. There is no unmarried accurate predictor of clinical outcomes of ICH that can exist helpful in determining whether withdrawal of technological support is appropriate. Most fatalities following ICH occur within the offset two days, and DNR orders are recommended to be postponed until at to the lowest degree the 2nd full day of hospitalization [4]. The DNR status should not limit advisable medical and surgical interventions, unless explicitly indicated past the patient or her/his family unit [4].
Surgical management
Infratentorial hemorrhage
Emergent surgery is strongly recommended in patients with a cerebellar hemorrhage with symptoms of neurological deterioration. Considering the posterior fossa has little complimentary space, cerebellar hemorrhage hands brings about brainstem compression, ventricular obstacle, hydrocephalus, and eventually high fatality. Patients with a cerebellar hemorrhage >three cm in diameter or patients in whom cerebellar hemorrhage is causing brainstem pinch or hydrocephalus can become better outcomes with surgical decompression through hematoma evacuation [four , 85 , 86]. Initial treatment of cerebellar hemorrhage with ventricular drainage solitary rather than surgical evacuation is non recommended due to insufficiency for ICP control [4].
As hematoma evacuation of a brainstem hemorrhage may be harmful in many cases, brainstem hemorrhage is usually managed conservatively [4 , 87 , 88]. Although there are several reports, which suggest that surgical treatment is effective in managing brainstem hemorrhages [89 - 91], the role of surgical direction in treating brainstem hemorrhages remains controversial.
Supratentorial hemorrhage
The benign furnishings of surgical management of supratentorial ICH remain controversial and should be restricted in specific situations. Although several randomized trials have compared the efficacy of surgical direction and conservative medical management, they accept not shown significant benefits of surgical management on mortality or functional outcomes [92 , 93].
The International Surgical Trial in Intracerebral Hemorrhage (STICH) was conducted to prove the superiority of early on hematoma evacuation (within 24 hours of randomization) over conservative medical treatment [92]. A total of one,033 patients were enrolled from 83 centers in 27 countries, and were randomized into early surgery (n=503) or initial conservative treatment (n=530) groups. The main outcome measure was the score on the 8-point extended Glasgow event scale at half dozen months. Of the 468 patients randomized to the early surgery group, 26% had favorable outcomes, compared to 24% of the 496 patients randomized to the initial conservative treatment group (OR, 0.89; 95% CI, 0.66–1.nineteen; P=0.414). The 6-calendar month bloodshed rate for the early surgery group was 36%, compared with 37% for the initial conservative treatment grouping (OR, 0.95; 95% CI, 0.73–1.23; P=0.707). Subgroup analysis revealed that patients with lobar hemorrhages within 1 cm of the cortical surface might benefit from surgery, while patients who presented as asleep (GCS score ≤eight) showed poorer outcomes following surgery. In this STICH trial, it was suggested that early on surgery could be beneficial in certain patients with superficial lobar hemorrhages, but there was no overall statistically pregnant difference in the mortality or functional consequence between the early surgery and initial conservative treatment groups.
In 2013, the results of the STICH II trial were published [93]. The STICH Two trial compared the outcomes of early surgery and initial conservative treatment in conscious patients with superficial lobar hemorrhage of 10–100 mL within ane cm of the cortical surface, with no IVH, and who were admitted within 48 hours of the onset of symptoms. A full of 601 patients were enrolled from 78 centers in 27 countries, and were randomized into the early surgery (n=307) or initial bourgeois handling (northward=294) groups. The primary outcome was a prognosis-based dichotomized (favorable or unfavorable) outcome on the 8-point extended Glasgow outcome scale at six months. Fifty-nine per centum of the patients in the early surgery group had an unfavorable consequence, compared with 62% of the patients in the initial conservative treatment grouping (OR, 0.86; 95% CI, 0.62–1.20; P=0.367). The 6-calendar month bloodshed rate was eighteen% in the early surgery group and 24% in the initial bourgeois treatment group (OR, 0.71; 95% CI, 0.48–1.06; P=0.095) [93]. Thus, these two large randomized trials failed to prove the do good of early surgical management with hematoma evacuation over initial conservative handling. Hematoma evacuation might exist considered as a life-saving measure out in patients with supratentorial hemorrhage showing neurological deterioration [4].
Previous studies have reported that patients with a GCS score <8, pregnant midline shift, large hematomas, or medically intractable ICP might do good from decompressive craniectomy [94 - 97]. Therefore, despite the failure of large clinical trials, information technology should be noted that decompressive surgery with or without hematoma evacuation might be helpful in reducing the bloodshed rate in these specific situations [4].
The role of minimally invasive surgical evacuation of ICH with stereotactic or endoscopic aspiration is unclear. Several studies have suggested that minimally invasive surgical evacuation might exist less invasive and have meliorate outcomes compared to a craniotomy arroyo [98 - 101]. In a randomized clinical trial conducted in Mainland china, needle aspiration of basal ganglia hemorrhages improved the 3-month functional outcome without significant improvement in mortality rate, compared to medical management alone [101]. Recently, the Minimally Invasive Surgery Plus Recombinant Tissue-Type Plasminogen Activator for ICH Evacuation Trial Ii (MISTIE II) reported a significant reduction in perihematomal edema in the hematoma evacuation group [100]. MISTIE III, a randomized stage 3 clinical trial, is ongoing.
Timing of decompressive surgery
On the footing of the subgroup analysis performed in the STICH II trial, surgery, if needed, should exist considered within 21 hours of ictus for better outcomes [4 , 93]. One meta-analysis indicated that there was improved outcome with surgery if randomization was undertaken within 8 hours of ictus [102]. Some other prospective report reported that surgical hematoma evacuation inside 4 hours of ictus was complicated by rebleeding, indicating difficulty with hemostasis [103]. Although more than evidence is needed to determine the timing of surgery, surgical management should not be delayed if patients show neurological deterioration, and surgical management tin can exist benign. The possible indications for the surgical management of ICH are described in Table 3.
Table 3.
Surgical candidates for ICH
| Situation | Surgical management |
|---|---|
| Cerebellar hemorrhage with neurological deterioration associated with brainstem pinch or hydrocephalus | Hematoma evacuation |
| Supratentorial hemorrhage with neurological deterioration | Hematoma evacuation |
| Supratentorial hemorrhage with GCS score < 8, pregnant midline shift and big hematomas, medically intractable ICP | Decompressive craniectomy |
| Hydrocephalus with or without IVH | Ventricular drainage |
Intraventricular hemorrhage
IVH is usually related to deep-seated ICH in the basal ganglia and/or thalamus. IVH is a crucial determinant of poor outcomes in patients with ICH [104]. Recently, ventricular catheter insertion with thrombolytic agents has been studied to overcome the inefficiency and difficulty of maintaining catheter patency. The Clear-IVH trial (Clot Lysis: Evaluating Accelerated Resolution of IVH) compared treatments with recombinant tissue-type plasminogen activator (rtPA) and placebo in patients with IVH attributable to spontaneous ICH [105 , 106]. Patients treated with rtPA had lower ICP and less frequent ventricular obstruction. The symptomatic rebleeding rate was not significantly dissimilar between the two groups (12% in the rtPA grouping, 5% in the placebo group, P=0.33); the median thirty-solar day modified Rankin scale score and mortality did not differ either. While rtPA seemed to have an adequate safety profile in the treatment of ICH with IVH, its efficacy and safety remain uncertain [4]. Data from a well-designed phase Three clinical trial, such as CLEAR 3, will be needed to fully evaluate the rubber and efficacy of this treatment.
Rehabilitation
Rehabilitation is strongly recommended in patients who have survived the acute phase of ICH merely are discharged from astute intendance hospitals with disability. The primary principles of rehabilitation for patients with ICH are similar to those for patients with ischemic stroke [4]. It has been repeatedly reported that the improvement of functional issue was significantly greater in patients receiving rehabilitation compared with those receiving standard medical care [107 , 108]. On the basis of our knowledge near stroke recovery, rehabilitation is recommended to be started as early as possible and should be continued in the community as part of a well-coordinated program of accelerated hospital discharge and dwelling-based resettlement to promote ongoing recovery [four].
Conclusion
In conclusion, in society to overcome the loftier bloodshed and morbidity, it is recommended that patients with spontaneous ICH should be taken care of in well-organized specialized stroke care facilities with a multidisciplinary squad arroyo. All the management principles including the close monitoring of vital signs and neurological status, rapid and adequate BP correction, proper ICP control and timely surgical direction of selected patients, prevention of complications, and early on rehabilitation are important for better clinical outcomes.
Footnotes
The authors have no financial conflicts of interest.
References
1. Feigin VL, Lawes CM, Bennett DA, Barker-Collo SL, Parag V. Worldwide stroke incidence and early case fatality reported in 56 population-based studies: a systematic review. Lancet Neurol. 2009;8:355–369. [PubMed] [Google Scholar]
2. Steiner T, Al-Shahi Salman R, Beer R, Christensen H, Cordonnier C, Csiba 50, et al. European Stroke Organisation (ESO) guidelines for the management of spontaneous intracerebral hemorrhage. Int J Stroke. 2014;ix:840–855. [PubMed] [Google Scholar]
three. van Asch CJ, Luitse MJ, Rinkel GJ, van der Tweel I, Algra A, Klijn CJ. Incidence, case fatality, and functional upshot of intracerebral haemorrhage over fourth dimension, co-ordinate to historic period, sex activity, and indigenous origin: a systematic review and meta-analysis. Lancet Neurol. 2010;9:167–176. [PubMed] [Google Scholar]
iv. Hemphill JC, third, Greenberg SM, Anderson CS, Becker M, Bendok BR, Cushman Yard, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: a guideline for healthcare professionals from the American Heart Association/American Stroke Clan. Stroke. 2015;46:2032–2060. [PubMed] [Google Scholar]
five. Hemphill JC, 3rd, Bonovich DC, Besmertis L, Manley GT, Johnston SC. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke. 2001;32:891–897. [PubMed] [Google Scholar]
six. Mayer SA, Rincon F. Treatment of intracerebral haemorrhage. Lancet Neurol. 2005;4:662–672. [PubMed] [Google Scholar]
7. Moon JS, Janjua N, Ahmed S, Kirmani JF, Harris-Lane P, Jacob M, et al. Prehospital neurologic deterioration in patients with intracerebral hemorrhage. Crit Care Med. 2008;36:172–175. [PubMed] [Google Scholar]
viii. Fan JS, Huang HH, Chen YC, Yen DH, Kao WF, Huang MS, et al. Emergency department neurologic deterioration in patients with spontaneous intracerebral hemorrhage: incidence, predictors, and prognostic significance. Acad Emerg Med. 2012;xix:133–138. [PubMed] [Google Scholar]
9. Chalela JA, Kidwell CS, Nentwich LM, Luby M, Butman JA, Demchuk AM, et al. Magnetic resonance imaging and computed tomography in emergency cess of patients with suspected astute stroke: a prospective comparison. Lancet. 2007;369:293–298. [PMC free article] [PubMed] [Google Scholar]
x. Fiebach JB, Schellinger PD, Gass A, Kucinski T, Siebler Thou, Villringer A, et al. Stroke magnetic resonance imaging is accurate in hyperacute intracerebral hemorrhage: a multicenter study on the validity of stroke imaging. Stroke. 2004;35:502–506. [PubMed] [Google Scholar]
11. Jauch EC, Saver JL, Adams HP, Jr, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Eye Clan/American Stroke Association. Stroke. 2013;44:870–947. [PubMed] [Google Scholar]
12. Andrews CM, Jauch EC, Hemphill JC, third, Smith WS, Weingart SD. Emergency neurological life support: intracerebral hemorrhage. Neurocrit Care. 2012;17 Suppl 1:S37–46. [PubMed] [Google Scholar]
xiii. Bernstein RA, Hemphill JC. Critical intendance of acute ischemic stroke. Curr Neurol Neurosci Rep. 2001;i:587–592. [PubMed] [Google Scholar]
xiv. Bruce SS, Appelboom K, Piazza 1000, Hwang BY, Kellner C, Carpenter AM, et al. A comparative evaluation of existing grading scales in intracerebral hemorrhage. Neurocrit Care. 2011;15:498–505. [PubMed] [Google Scholar]
15. Hemphill JC, 3rd, Farrant M, Neill TA., Jr Prospective validation of the ICH Score for 12-calendar month functional outcome. Neurology. 2009;73:1088–1094. [PMC complimentary article] [PubMed] [Google Scholar]
16. Ji R, Shen H, Pan Y, Wang P, Liu M, Wang Y, et al. A novel risk score to predict one-year functional outcome after intracerebral hemorrhage and comparing with existing scores. Crit Care. 2013;17:R275. [PMC gratuitous commodity] [PubMed] [Google Scholar]
17. Rost NS, Smith EE, Chang Y, Snider RW, Chanderraj R, Schwab K, et al. Prediction of functional outcome in patients with primary intracerebral hemorrhage: the FUNC score. Stroke. 2008;39:2304–2309. [PubMed] [Google Scholar]
18. Sun Westward, Pan W, Kranz PG, Hailey CE, Williamson RA, Sun West, et al. Predictors of tardily neurological deterioration later spontaneous intracerebral hemorrhage. Neurocrit Care. 2013;nineteen:299–305. [PMC costless article] [PubMed] [Google Scholar]
19. Leira R, Davalos A, Silva Y, Gil-Peralta A, Tejada J, Garcia Yard, et al. Early on neurologic deterioration in intracerebral hemorrhage: predictors and associated factors. Neurology. 2004;63:461–467. [PubMed] [Google Scholar]
xx. Sorimachi T, Fujii Y. Early on neurological change in patients with spontaneous supratentorial intracerebral hemorrhage. J Clin Neurosci. 2010;17:1367–1371. [PubMed] [Google Scholar]
21. Diringer MN, Edwards DF. Admission to a neurologic/neurosurgical intensive intendance unit is associated with reduced mortality rate afterwards intracerebral hemorrhage. Crit Care Med. 2001;29:635–640. [PubMed] [Google Scholar]
22. Terent A, Asplund Thou, Farahmand B, Henriksson KM, Norrving B, Stegmayr B, et al. Stroke unit care revisited: who benefits the most? A cohort study of 105,043 patients in Riks-Stroke, the Swedish Stroke Register. J Neurol Neurosurg Psychiatry. 2009;80:881–887. [PubMed] [Google Scholar]
23. Rodriguez-Luna D, Pineiro S, Rubiera Thousand, Ribo 1000, Coscojuela P, Pagola J, et al. Impact of blood pressure changes and class on hematoma growth in acute intracerebral hemorrhage. Eur J Neurol. 2013;20:1277–1283. [PubMed] [Google Scholar]
24. Sakamoto Y, Koga 1000, Yamagami H, Okuda South, Okada Y, Kimura Thou, et al. Systolic blood pressure afterward intravenous antihypertensive treatment and clinical outcomes in hyperacute intracerebral hemorrhage: the stroke acute management with urgent gamble-cistron cess and comeback-intracerebral hemorrhage written report. Stroke. 2013;44:1846–1851. [PubMed] [Google Scholar]
25. Zhang Y, Reilly KH, Tong Due west, Xu T, Chen J, Bazzano LA, et al. Blood pressure level and clinical effect among patients with acute stroke in Inner Mongolia, Mainland china. J Hypertens. 2008;26:1446–1452. [PubMed] [Google Scholar]
26. Naval NS, Nyquist PA, Carhuapoma JR. Direction of spontaneous intracerebral hemorrhage. Neurol Clin. 2008;26:373–384. vii. [PubMed] [Google Scholar]
27. Butcher KS, Jeerakathil T, Hill M, Demchuk AM, Dowlatshahi D, Coutts SB, et al. The intracerebral hemorrhage acutely decreasing arterial pressure trial. Stroke. 2013;44:620–626. [PubMed] [Google Scholar]
28. Anderson CS, Heeley Eastward, Huang Y, Wang J, Stapf C, Delcourt C, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. N Engl J Med. 2013;368:2355–2365. [PubMed] [Google Scholar]
29. Anderson CS, Huang Y, Wang JG, Arima H, Neal B, Peng B, et al. Intensive blood pressure reduction in acute cerebral bleeding trial (Interact): a randomised pilot trial. Lancet Neurol. 2008;7:391–399. [PubMed] [Google Scholar]
30. Qureshi AI, Palesch YY, Martin R, Novitzke J, Cruz-Flores South, Ehtisham A, et al. Effect of systolic blood force per unit area reduction on hematoma expansion, perihematomal edema, and 3-month outcome amongst patients with intracerebral hemorrhage: results from the antihypertensive handling of acute cerebral hemorrhage written report. Curvation Neurol. 2010;67:570–576. [PMC complimentary commodity] [PubMed] [Google Scholar]
31. Adeoye O, Broderick JP. Advances in the management of intracerebral hemorrhage. Nat Rev Neurol. 2010;half dozen:593–601. [PubMed] [Google Scholar]
32. Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, et al. Intensive claret-pressure lowering in patients with acute cerebral hemorrhage. N Engl J Med. 2016;375:1033–1043. [PMC gratis commodity] [PubMed] [Google Scholar]
33. Eikelboom JW, Quinlan DJ, van Ryn J, Weitz JI. Idarucizumab: the antidote for reversal of dabigatran. Circulation. 2015;132:2412–2422. [PubMed] [Google Scholar]
34. Pollack CV, Jr, Reilly PA, Eikelboom J, Glund South, Verhamme P, Bernstein RA, et al. Idarucizumab for dabigatran reversal. Due north Engl J Med. 2015;373:511–520. [PubMed] [Google Scholar]
35. Schreuder FH, Sato S, Klijn CJ, Anderson CS. Medical management of intracerebral bleeding. J Neurol Neurosurg Psychiatry. 2017;88:76–84. [PubMed] [Google Scholar]
36. Connolly SJ, Milling TJ, Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gilded A, et al. Andexanet alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med. 2016;375:1131–1141. [PMC costless article] [PubMed] [Google Scholar]
37. Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley Atomic number 82, Wiens BL, et al. Andexanet alfa for the reversal of gene Xa inhibitor activity. Due north Engl J Med. 2015;373:2413–2424. [PubMed] [Google Scholar]
38. Konkle BA. Monitoring target specific anticoagulants. J Thromb Thrombolysis. 2013;35:387–390. [PubMed] [Google Scholar]
39. Tran H, Joseph J, Young L, McRae S, Curnow J, Nandurkar H, et al. New oral anticoagulants: a practical guide on prescription, laboratory testing and peri-procedural/haemorrhage direction. Australasian Society of Thrombosis and Haemostasis. Intern Med J. 2014;44:525–536. [PubMed] [Google Scholar]
40. Douxfils J, Mullier F, Robert S, Chatelain C, Chatelain B, Dogne JM. Impact of dabigatran on a large console of routine or specific coagulation assays. Laboratory recommendations for monitoring of dabigatran etexilate. Thromb Haemost. 2012;107:985–997. [PubMed] [Google Scholar]
41. Harenberg J, Giese C, Marx S, Kramer R. Determination of dabigatran in human being plasma samples. Semin Thromb Hemost. 2012;38:xvi–22. [PubMed] [Google Scholar]
42. Lindahl TL, Baghaei F, Blixter IF, Gustafsson KM, Stigendal L, Sten-Linder Grand, et al. Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays. Thromb Haemost. 2011;105:371–378. [PubMed] [Google Scholar]
43. Harenberg J, Erdle Due south, Marx Southward, Kramer R. Determination of rivaroxaban in human plasma samples. Semin Thromb Hemost. 2012;38:178–184. [PubMed] [Google Scholar]
44. Douxfils J, Chatelain C, Chatelain B, Dogne JM, Mullier F. Impact of apixaban on routine and specific coagulation assays: a practical laboratory guide. Thromb Haemost. 2013;110:283–294. [PubMed] [Google Scholar]
45. Kuramatsu JB, Gerner ST, Schellinger PD, Glahn J, Endres 1000, Sobesky J, et al. Anticoagulant reversal, blood force per unit area levels, and anticoagulant resumption in patients with anticoagulation-related intracerebral hemorrhage. JAMA. 2015;313:824–836. [PubMed] [Google Scholar]
46. Poli D, Antonucci E, Dentali F, Erba N, Testa South, Tiraferri East, et al. Recurrence of ICH later resumption of anticoagulation with VK antagonists: CHIRONE study. Neurology. 2014;82:1020–1026. [PubMed] [Google Scholar]
47. Majeed A, Kim YK, Roberts RS, Holmstrom Grand, Schulman S. Optimal timing of resumption of warfarin later on intracranial hemorrhage. Stroke. 2010;41:2860–2866. [PubMed] [Google Scholar]
48. Eckman MH, Rosand J, Knudsen KA, Singer DE, Greenberg SM. Can patients be anticoagulated later intracerebral hemorrhage? A decision assay. Stroke. 2003;34:1710–1716. [PubMed] [Google Scholar]
49. Schulman South. Resumption of oral anticoagulation subsequently warfarin-associated intracerebral hemorrhage: no. Stroke. 2011;42:3663–3664. [PubMed] [Google Scholar]
50. Biffi A, Halpin A, Towfighi A, Gilson A, Busl One thousand, Rost N, et al. Aspirin and recurrent intracerebral hemorrhage in cognitive amyloid angiopathy. Neurology. 2010;75:693–698. [PMC free commodity] [PubMed] [Google Scholar]
51. Flynn RW, MacDonald TM, Murray GD, MacWalter RS, Doney Every bit. Prescribing antiplatelet medicine and subsequent events afterward intracerebral hemorrhage. Stroke. 2010;41:2606–2611. [PubMed] [Google Scholar]
52. Investigators A, Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. Northward Engl J Med. 2009;360:2066–2078. [PubMed] [Google Scholar]
53. Connolly SJ, Ezekowitz Medico, Yusuf South, Eikelboom J, Oldgren J, Parekh A, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009;361:1139–1151. [PubMed] [Google Scholar]
54. Granger CB, Alexander JH, McMurray JJ, Lopes RD, Hylek EM, Hanna M, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981–992. [PubMed] [Google Scholar]
55. Patel MR, Mahaffey KW, Garg J, Pan G, Singer DE, Hacke W, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883–891. [PubMed] [Google Scholar]
56. Naidech AM, Bernstein RA, Levasseur K, Bassin SL, Bendok BR, Batjer HH, et al. Platelet activity and outcome after intracerebral hemorrhage. Ann Neurol. 2009;65:352–356. [PubMed] [Google Scholar]
57. Naidech AM, Jovanovic B, Liebling S, Garg RK, Bassin SL, Bendok BR, et al. Reduced platelet activity is associated with early jell growth and worse iii-month upshot later intracerebral hemorrhage. Stroke. 2009;forty:2398–2401. [PubMed] [Google Scholar]
58. Sansing LH, Messe SR, Cucchiara BL, Cohen SN, Lyden PD, Kasner SE, et al. Prior antiplatelet utilise does not affect hemorrhage growth or outcome afterwards ICH. Neurology. 2009;72:1397–1402. [PMC gratis commodity] [PubMed] [Google Scholar]
59. de Gans K, de Haan RJ, Majoie CB, Koopman MM, Brand A, Dijkgraaf MG, et al. PATCH: platelet transfusion in cognitive haemorrhage: study protocol for a multicentre, randomised, controlled trial. BMC Neurol. 2010;10:nineteen. [PMC costless article] [PubMed] [Google Scholar]
threescore. Chan S, Hemphill JC., tertiary Critical care management of intracerebral hemorrhage. Crit Care Clin. 2014;30:699–717. [PubMed] [Google Scholar]
61. Collaboration CT. Thigh-length versus below-knee stockings for deep venous thrombosis prophylaxis subsequently stroke: a randomized trial. Ann Intern Med. 2010;153:553–562. [PubMed] [Google Scholar]
62. Collaboration CT, Dennis K, Sandercock P, Reid J, Graham C, Forbes J, et al. Effectiveness of intermittent pneumatic pinch in reduction of risk of deep vein thrombosis in patients who have had a stroke (CLOTS 3): a multicentre randomised controlled trial. Lancet. 2013;382:516–524. [PubMed] [Google Scholar]
63. Collaboration CT, Dennis M, Sandercock P, Reid J, Graham C, Murray G, et al. The effect of graduated pinch stockings on long-term outcomes after stroke: the CLOTS trials 1 and 2. Stroke. 2013;44:1075–1079. [PubMed] [Google Scholar]
64. Collaboration CT, Dennis Thousand, Sandercock PA, Reid J, Graham C, Murray G, et al. Effectiveness of thigh-length graduated compression stockings to reduce the risk of deep vein thrombosis after stroke (CLOTS trial one): a multicentre, randomised controlled trial. Lancet. 2009;373:1958–1965. [PMC gratuitous article] [PubMed] [Google Scholar]
65. Paciaroni M, Agnelli K, Venti M, Alberti A, Acciarresi M, Caso V. Efficacy and safety of anticoagulants in the prevention of venous thromboembolism in patients with acute cerebral hemorrhage: a meta-assay of controlled studies. J Thromb Haemost. 2011;9:893–898. [PubMed] [Google Scholar]
66. Guyatt GH, Akl EA, Crowther 1000, Gutterman DD, Schuunemann HJ, American College of Chest Physicians Antithrombotic T et al. Executive summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:7S–47S. [PMC gratuitous article] [PubMed] [Google Scholar]
67. Kamel H, Hemphill JC., 3rd Characteristics and sequelae of intracranial hypertension after intracerebral hemorrhage. Neurocrit Care. 2012;17:172–176. [PubMed] [Google Scholar]
68. Kamel H, Navi BB, Nakagawa Chiliad, Hemphill JC, 3rd, Ko NU. Hypertonic saline versus mannitol for the treatment of elevated intracranial force per unit area: a meta-assay of randomized clinical trials. Crit Care Med. 2011;39:554–559. [PubMed] [Google Scholar]
69. Poungvarin N, Bhoopat Due west, Viriyavejakul A, Rodprasert P, Buranasiri P, Sukondhabhant Southward, et al. Effects of dexamethasone in primary supratentorial intracerebral hemorrhage. Due north Engl J Med. 1987;316:1229–1233. [PubMed] [Google Scholar]
70. Schwarz S, Hafner M, Aschoff A, Schwab S. Incidence and prognostic significance of fever following intracerebral hemorrhage. Neurology. 2000;54:354–361. [PubMed] [Google Scholar]
71. Kollmar R, Staykov D, Dorfler A, Schellinger PD, Schwab S, Bardutzky J. Hypothermia reduces perihemorrhagic edema after intracerebral hemorrhage. Stroke. 2010;41:1684–1689. [PubMed] [Google Scholar]
72. Fingas Chiliad, Penner M, Silasi G, Colbourne F. Treatment of intracerebral hemorrhage in rats with 12 h, 3 days and 6 days of selective encephalon hypothermia. Exp Neurol. 2009;219:156–162. [PubMed] [Google Scholar]
73. Fogelholm R, Murros K, Rissanen A, Avikainen Southward. Access blood glucose and short term survival in principal intracerebral haemorrhage: a population based study. J Neurol Neurosurg Psychiatry. 2005;76:349–353. [PMC free article] [PubMed] [Google Scholar]
74. Investigators N-SS. Finfer South, Chittock DR, Su SY, Blair D, Foster D, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009;360:1283–1297. [PubMed] [Google Scholar]
75. Vespa P, Boonyaputthikul R, McArthur DL, Miller C, Etchepare One thousand, Bergsneider M, et al. Intensive insulin therapy reduces microdialysis glucose values without altering glucose utilization or improving the lactate/pyruvate ratio after traumatic brain injury. Crit Intendance Med. 2006;34:850–856. [PubMed] [Google Scholar]
76. Bladin CF, Alexandrov AV, Bellavance A, Bornstein North, Chambers B, Cote R, et al. Seizures after stroke: a prospective multicenter study. Arch Neurol. 2000;57:1617–1622. [PubMed] [Google Scholar]
77. Claassen J, Jette N, Chum F, Green R, Schmidt M, Choi H, et al. Electrographic seizures and periodic discharges afterwards intracerebral hemorrhage. Neurology. 2007;69:1356–1365. [PubMed] [Google Scholar]
78. Szaflarski JP, Rackley AY, Kleindorfer DO, Khoury J, Woo D, Miller R, et al. Incidence of seizures in the astute phase of stroke: a population-based study. Epilepsia. 2008;49:974–981. [PMC free commodity] [PubMed] [Google Scholar]
79. Beghi East, D'Alessandro R, Beretta S, Consoli D, Crespi V, Delaj L, et al. Incidence and predictors of acute symptomatic seizures after stroke. Neurology. 2011;77:1785–1793. [PubMed] [Google Scholar]
80. De Herdt V, Dumont F, Henon H, Derambure P, Vonck K, Leys D, et al. Early seizures in intracerebral hemorrhage: incidence, associated factors, and event. Neurology. 2011;77:1794–1800. [PubMed] [Google Scholar]
81. Lyden PD, Shuaib A, Lees KR, Davalos A, Davis SM, Diener HC, et al. Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: the Chant Trial. Stroke. 2007;38:2262–2269. [PubMed] [Google Scholar]
82. Maramattom BV, Weigand South, Reinalda M, Wijdicks EF, Manno EM. Pulmonary complications after intracerebral hemorrhage. Neurocrit Care. 2006;v:115–119. [PubMed] [Google Scholar]
83. Hinchey JA, Shephard T, Furie K, Smith D, Wang D, Tonn Due south, et al. Formal dysphagia screening protocols prevent pneumonia. Stroke. 2005;36:1972–1976. [PubMed] [Google Scholar]
84. Holloway RG, Arnold RM, Creutzfeldt CJ, Lewis EF, Lutz BJ, McCann RM, et al. Palliative and terminate-of-life care in stroke: a argument for healthcare professionals from the American Heart Association/American Stroke Clan. Stroke. 2014;45:1887–1916. [PubMed] [Google Scholar]
85. Da Pian R, Bazzan A, Pasqualin A. Surgical versus medical treatment of spontaneous posterior fossa haematomas: a cooperative study on 205 cases. Neurol Res. 1984;6:145–151. [PubMed] [Google Scholar]
86. Firsching R, Huber Chiliad, Frowein RA. Cerebellar bleeding: management and prognosis. Neurosurg Rev. 1991;xiv:191–194. [PubMed] [Google Scholar]
87. Komiyama M, Boo YE, Yagura H, Yasui T, Baba K, Hakuba A, et al. A clinical assay of 32 brainstem haemorrhages; with special reference to surviving but severely disabled cases. Acta Neurochir (Wien) 1989;101:46–51. [PubMed] [Google Scholar]
88. Manno EM, Atkinson JL, Fulgham JR, Wijdicks EF. Emerging medical and surgical management strategies in the evaluation and treatment of intracerebral hemorrhage. Mayo Clin Proc. 2005;lxxx:420–433. [PubMed] [Google Scholar]
89. Hara T, Nagata K, Kawamoto Southward, Sashida J, Abe T, Wada A, et al. [Functional effect of primary pontine hemorrhage: conservative handling or stereotaxic surgery] No Shinkei Geka. 2001;29:823–829. [PubMed] [Google Scholar]
90. Mangiardi JR, Epstein FJ. Brainstem haematomas: review of the literature and presentation of five new cases. J Neurol Neurosurg Psychiatry. 1988;51:966–976. [PMC gratuitous article] [PubMed] [Google Scholar]
91. Takahama H, Morii Thou, Sato K, Sekiguchi K, Sato S. [Stereotactic aspiration in hypertensive pontine hemorrhage: comparative report with conservative therapy] No Shinkei Geka. 1989;17:733–739. [PubMed] [Google Scholar]
92. Mendelow AD, Gregson BA, Fernandes HM, Murray GD, Teasdale GM, Hope DT, et al. Early on surgery versus initial conservative handling in patients with spontaneous supratentorial intracerebral haematomas in the International Surgical Trial in Intracerebral Haemorrhage (STICH): a randomised trial. Lancet. 2005;365:387–397. [PubMed] [Google Scholar]
93. Mendelow AD, Gregson BA, Rowan EN, Murray GD, Gholkar A, Mitchell PM, et al. Early surgery versus initial conservative treatment in patients with spontaneous supratentorial lobar intracerebral haematomas (STICH 2): a randomised trial. Lancet. 2013;382:397–408. [PMC free article] [PubMed] [Google Scholar]
94. Fung C, Murek M, Z'Graggen WJ, Krahenbuhl AK, Gautschi OP, Schucht P, et al. Decompressive hemicraniectomy in patients with supratentorial intracerebral hemorrhage. Stroke. 2012;43:3207–3211. [PubMed] [Google Scholar]
95. Hayes SB, Benveniste RJ, Morcos JJ, Aziz-Sultan MA, Elhammady MS. Retrospective comparison of craniotomy and decompressive craniectomy for surgical evacuation of nontraumatic, supratentorial intracerebral hemorrhage. Neurosurg Focus. 2013;34:E3. [PubMed] [Google Scholar]
96. Heuts SG, Bruce SS, Zacharia BE, Hickman ZL, Kellner CP, Sussman ES, et al. Decompressive hemicraniectomy without jell evacuation in dominant-sided intracerebral hemorrhage with ICP crisis. Neurosurg Focus. 2013;34:E4. [PubMed] [Google Scholar]
97. Takeuchi S, Wada M, Nagatani Yard, Otani N, Mori K. Decompressive hemicraniectomy for spontaneous intracerebral hemorrhage. Neurosurg Focus. 2013;34:E5. [PubMed] [Google Scholar]
98. Auer LM, Deinsberger W, Niederkorn K, Gell G, Kleinert R, Schneider Thou, et al. Endoscopic surgery versus medical handling for spontaneous intracerebral hematoma: a randomized report. J Neurosurg. 1989;seventy:530–535. [PubMed] [Google Scholar]
99. Morgan T, Zuccarello K, Narayan R, Keyl P, Lane Chiliad, Hanley D. Preliminary findings of the minimally-invasive surgery plus rtPA for intracerebral hemorrhage evacuation (MISTIE) clinical trial. Acta Neurochir Suppl. 2008;105:147–151. [PubMed] [Google Scholar]
100. Mould WA, Carhuapoma JR, Muschelli J, Lane M, Morgan TC, McBee NA, et al. Minimally invasive surgery plus recombinant tissue-blazon plasminogen activator for intracerebral hemorrhage evacuation decreases perihematomal edema. Stroke. 2013;44:627–634. [PMC gratis article] [PubMed] [Google Scholar]
101. Wang WZ, Jiang B, Liu HM, Li D, Lu CZ, Zhao YD, et al. Minimally invasive craniopuncture therapy vs. conservative treatment for spontaneous intracerebral hemorrhage: results from a randomized clinical trial in Prc. Int J Stroke. 2009;4:eleven–16. [PubMed] [Google Scholar]
102. Gregson BA, Broderick JP, Auer LM, Batjer H, Chen XC, Juvela Southward, et al. Individual patient data subgroup meta-analysis of surgery for spontaneous supratentorial intracerebral hemorrhage. Stroke. 2012;43:1496–1504. [PMC gratis commodity] [PubMed] [Google Scholar]
103. Morgenstern LB, Demchuk AM, Kim DH, Frankowski RF, Grotta JC. Rebleeding leads to poor outcome in ultra-early on craniotomy for intracerebral hemorrhage. Neurology. 2001;56:1294–1299. [PubMed] [Google Scholar]
104. Hallevi H, Albright KC, Aronowski J, Barreto AD, Martin-Schild South, Khaja AM, et al. Intraventricular hemorrhage: Anatomic relationships and clinical implications. Neurology. 2008;70:848–852. [PMC costless article] [PubMed] [Google Scholar]
105. Morgan T, Awad I, Keyl P, Lane K, Hanley D. Preliminary report of the clot lysis evaluating accelerated resolution of intraventricular hemorrhage (CLEAR-IVH) clinical trial. Acta Neurochir Suppl. 2008;105:217–220. [PubMed] [Google Scholar]
106. Naff N, Williams MA, Keyl PM, Tuhrim S, Bullock MR, Mayer SA, et al. Low-dose recombinant tissue-type plasminogen activator enhances jell resolution in brain hemorrhage: the intraventricular hemorrhage thrombolysis trial. Stroke. 2011;42:3009–3016. [PMC gratuitous article] [PubMed] [Google Scholar]
107. Bai Y, Hu Y, Wu Y, Zhu Y, He Q, Jiang C, et al. A prospective, randomized, single-blinded trial on the result of early on rehabilitation on daily activities and motor office of patients with hemorrhagic stroke. J Clin Neurosci. 2012;nineteen:1376–1379. [PubMed] [Google Scholar]
108. Cumming TB, Austerity AG, Collier JM, Churilov L, Dewey HM, Donnan GA, et al. Very early mobilization later stroke fast-tracks render to walking: further results from the phase II AVERT randomized controlled trial. Stroke. 2011;42:153–158. [PubMed] [Google Scholar]
Articles from Periodical of Stroke are provided here courtesy of Korean Stroke Club
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5307946/
0 Response to "Mannitol for Posterior Fossa Hemorrhage Systematic Review Ncbi"
Post a Comment